Literature DB >> 9330072

The impact of onychomycosis on quality of life.

L R Whittam1, R J Hay.   

Abstract

Onychomycosis is a common disease, which is estimated to affect approximately 3% of the UK population. It is often viewed as being relatively trivial in nature; however, there has been little research to evaluate how this condition affects patients' physical and psychological well-being. The aim of this study was to assess the possible effect of onychomycosis on different aspects of patients' quality of life.

Entities:  

Mesh:

Year:  1997        PMID: 9330072

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  10 in total

1.  Skin and nail fungi-almost beaten.

Authors:  A Y Finlay
Journal:  BMJ       Date:  1999-07-10

2.  Inappropriate use of oral terbinafine in family practice.

Authors:  Michael Wilcock; John Hartley; David Gould
Journal:  Pharm World Sci       Date:  2003-02

3.  A health-related quality of life measure for use in patients with onychomycosis: a validation study.

Authors:  D P Lubeck; D Gause; J R Schein; L E Prebil; L P Potter
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

Review 4.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 5.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 7.  Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Authors:  Jenny Wang; Lauren E Wiznia; Evan A Rieder
Journal:  Skin Appendage Disord       Date:  2017-04-21

Review 8.  Onychomycosis: health-related quality of life considerations.

Authors:  James W Shaw; Vijay N Joish; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 9.  Management of onychomycoses.

Authors:  M Niewerth; H C Korting
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 10.  The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.